Market estimated to grow at CAGR of 20% from 2021 to 2028 due to an exponential rise in clinical pipeline along with rising number of regulatory approvals.
Will leverage integrated services from Selexis and KBI as part of Immatics’ development of TCR Bispecifics, designed to detect, target and attack tumor cells.
Lonza’s Robert Beland discusses best practices for manufacturers to shorten development timelines, as well as some of the capabilities at the CDMO's Tampa site.
Increases capabilities and capacity to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens.
Advanced BioScience Laboratories, Inc. (ABL) has opened its new research and manufacturing facility following the expansion of its vaccine and biotherapeutic product development capabilities at its new headquarters in Rockville, MD.
Richman Chemical, Inc. has expanded its service offerings to include biotechnology services ranging from cell line development to media optimization and process characterization.
ShangPharma Corp. began operations on the initial phase of production at its new pharmaceutical development and cGMP manufacturing facility in Fengxian, China.
AMT has entered into an agreement with Institut Pasteur, and a group of French research institutes (the "Consortium"), to support clinical development of a gene therapy to treat Sanfilippo B.
DSM BioSolutions has entered into an agreement with Novacta Biosystems Ltd. for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.
Goodwin Biotechnology Inc., a full service contract biomanufacturing company, and Hyprocell LLC, a provider of clinical cell line development services, have entered into a collaboration agreement to create a business model enabling customers to access the
Cytovance Biologics and Selexys Pharmaceutical have entered an agreement for the execution of a biopharmaceutical development and manufacturing collaboration for Anti-PSGL-1, a monoclonal antibody (mAb) being developed for treatment of inflammation associ
Bio-Processing Alliance, Inc. (BPAI) has launched a biologics drug development consulting business to provide support the management of complex biologics programs from concept, through to development and Phase I-III trials.
Avid Bioservices, Inc. and Boehringer Ingelheim have entered into a global strategic production alliance agreement, under which Avid will become an approved member of BI's global Production Alliance Network (PAN) Biologics.
Evotec AG has entered into a research agreement with Biogen Idec, under which Evotec will use its protein production technologies, assay development and high throughput screening to identify hit molecules for Biogen.
Selexis SA and NKT Therapeutics (NKTT) have entered into a research services agreement under which Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their INTEGRA-D2M platform.